Stock Events

Stock Events

Larimar Therapeutics 

€4.4
24
+€0.12+2.8% Today

Statistics

Day High
4.4
Day Low
4.4
52W High
5.25
52W Low
1.5
Volume
-
Avg. Volume
-
Mkt Cap
376.6M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.73
-0.57
-0.4
-0.24
Expected EPS
-0.546265
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-153.4MNet Income

Analyst Ratings

$10.24Average Price Target
The highest estimate is 10.62.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ZA71.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.44B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for rare diseases, similar to Larimar's focus on genetic disorders.
PTC Therapeutics
PTCT
Mkt Cap5.7B
PTC Therapeutics operates in the field of genetic disorders, particularly targeting Duchenne muscular dystrophy and cystic fibrosis, overlapping with Larimar's therapeutic areas.
Solid Biosciences
SLDB
Mkt Cap736.95M
Solid Biosciences is involved in developing therapies for Duchenne muscular dystrophy, a key area of focus for Larimar Therapeutics.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for rare diseases and medical conditions, competing in the same space as Larimar.
Ultragenyx Pharmaceutical
RARE
Mkt Cap2.21B
Ultragenyx Pharmaceutical focuses on rare and ultra-rare diseases, directly competing with Larimar in the niche market of genetic disorders.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is engaged in the development of gene-based therapies, which could potentially address the same genetic disorders as Larimar's treatments.
Editas Medicine
EDIT
Mkt Cap261.32M
Editas Medicine works on editing genes to treat genetic diseases, posing a direct competition to Larimar's gene therapy approach.
Intellia Therapeutics
NTLA
Mkt Cap1.55B
Intellia Therapeutics is a leading company in gene editing for the treatment of genetic diseases, competing in the same innovative space as Larimar.
uniQure N.V.
QURE
Mkt Cap1.07B
uniQure is known for its work in gene therapy targeting hemophilia, but its platform could be adapted to compete with Larimar's focus areas.

About

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Show more...
CEO
Dr. Carole S. Ben-Maimon M.D.
Employees
71
Country
DE
ISIN
US5171251003
WKN
000A2P5PP

Listings

XNAS
US
LRMR
F
DE
ZA71.F
BOATS
BOATS
LRMR.BOATS

0 Comments

Share your thoughts

FAQ

What is Larimar Therapeutics stock price today?▼
The current price of ZA71.F is €4.4 EUR — it has increased by +2.8% in the past 24 hours. Watch Larimar Therapeutics stock price performance more closely on the chart.
What is Larimar Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Larimar Therapeutics stocks are traded under the ticker ZA71.F.
Is Larimar Therapeutics stock price growing?▼
ZA71.F stock has risen by +15.18% compared to the previous week, the month change is a +0% rise, over the last year Larimar Therapeutics has showed a +155.81% increase.
What is Larimar Therapeutics market cap?▼
Today Larimar Therapeutics has the market capitalization of 376.6M
When is the next Larimar Therapeutics earnings date?▼
Larimar Therapeutics is going to release the next earnings report on May 07, 2026.
What were Larimar Therapeutics earnings last quarter?▼
ZA71.F earnings for the last quarter are -0.63 EUR per share, whereas the estimation was -0.42 EUR resulting in a -49.19% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Larimar Therapeutics revenue for the last year?▼
Larimar Therapeutics revenue for the last year amounts to 0 EUR.
What is Larimar Therapeutics net income for the last year?▼
ZA71.F net income for the last year is -153.4M EUR.
How many employees does Larimar Therapeutics have?▼
As of April 08, 2026, the company has 71 employees.
In which sector is Larimar Therapeutics located?▼
Larimar Therapeutics operates in the Health Care sector.
When did Larimar Therapeutics complete a stock split?▼
The last stock split for Larimar Therapeutics was on May 29, 2020 with a ratio of 1:12.
Where is Larimar Therapeutics headquartered?▼
Larimar Therapeutics is headquartered in Bala Cynwyd, DE.